RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11

Bicycle Therapeutics plc (NASDAQ:BCYC) is one of the 7 Fastest Growing European Stocks to Invest In. On March 18, 2026, RBC Capital lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $7 from $11 and maintained a Sector Perform rating, citing the company’s pivot away from zelenectide as a near-term setback that reduces visibility toward commercialization, though restructuring efforts could generate meaningful cost savings and support a longer-term reset.

On the same day, Oppenheimer analyst Jay Olson lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $36 from $44 and maintained an Outperform rating, noting the company’s decision to deprioritize zelenectide-pevedotin despite encouraging data, with resources being redirected toward BT5528 and next-generation programs, including its radio-conjugates portfolio.

On March 17, 2026, Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q4 EPS of (29c), compared to the (95c) consensus estimate, with revenue of $47.96M versus $7.08M consensus. The company said the increase in revenue was primarily driven by recognition of remaining collaboration revenue following termination notices with partners, including Novartis and Bayer. CEO Kevin Lee said the company completed dose selection in the Duravelo-2 trial but, following regulatory feedback, decided to deprioritize zelenectide for internal development and shift focus toward other pipeline programs, alongside a broader strategic reprioritization that includes a proposed workforce reduction.

Bicycle Therapeutics plc (NASDAQ:BCYC) develops novel therapeutics for diseases with limited treatment options.

While we acknowledge the risk and potential of BCYC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BCYC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.